tldrdailynews.com logo
Tag

Ozempic

All articles tagged with #ozempic

GLP-1 Weight Drugs: Debunking the 'bones-shredding' myth
health22 hours ago

GLP-1 Weight Drugs: Debunking the 'bones-shredding' myth

A viral claim that GLP-1 drugs like semaglutide (Ozempic) shred bones isn’t supported. A preliminary AAOS presentation linked GLP-1 use with higher rates of osteoporosis and osteomalacia, but the absolute numbers were small (about 4% and 2%), and weight loss itself may drive risk. Doctors advise monitoring bone health and preventive steps (calcium, vitamin D, strength training). Another study at the same conference suggested GLP-1s could reduce some postoperative complications in orthopedic patients. GLP-1s have GI side effects and potential eye risks, but their overall benefits for obesity and diabetes remain substantial; the key is weighing benefits against risks with a clinician and avoiding sensational myths.

via Gizmodo|
#bone-health#glp-1s#health
GLP-1 Weight Loss Sparks Relationship Shifts, Experts Warn
lifestyle23 hours ago

GLP-1 Weight Loss Sparks Relationship Shifts, Experts Warn

GLP-1 weight-loss medications may trigger changes in relationship dynamics after substantial weight loss, including increased autonomy and social activity that can strain partnerships; experts warn of a possible rise in separations or divorce as couples adjust, with reports of shifts in libido and intimacy. Some suggest couples therapy or undertaking the weight-loss journey together to mitigate the impact.

via The Daily Beast|
#divorce#glp-1#lifestyle
Heart protection from GLP-1 drugs fades quickly after stopping, study finds
health17 days ago

Heart protection from GLP-1 drugs fades quickly after stopping, study finds

A Washington University study of more than 333,000 U.S. veterans with type 2 diabetes found that continuous GLP-1 therapy reduced cardiovascular risk by about 18% after three years; stopping the medication for six months raised risk by 4%, after one year by 14%, and after two years by 22%, with restarting yielding only partial protection, highlighting the importance of long‑term use and accompanying lifestyle changes.

via AOL.com|
#bmj-medicine#cardiovascular-risk#glp-1-drugs
Halting GLP-1 Meds Erases Cardiovascular Gains
heart-health21 days ago

Halting GLP-1 Meds Erases Cardiovascular Gains

A BMJ Medicine study of 333,687 veterans shows that stopping GLP-1 therapies (like Ozempic and Wegovy) reverses their cardiovascular benefits quickly: even a 6‑month lapse raises the risk of heart attack and stroke, and longer interruptions erode protection further. Continuous GLP-1 use was linked to fewer major cardiovascular events, while stopping can also lead to weight regain and withdrawal symptoms; tapering off with medical guidance and maintaining a healthy lifestyle is advised, underscoring that GLP-1 benefits are long‑term risk‑reduction rather than a quick fix.

via Healthline|
#cardiovascular#discontinuation#glp-1
Heart Risk Surges Within Months of Quitting GLP-1 Diabetes Drugs
health23 days ago

Heart Risk Surges Within Months of Quitting GLP-1 Diabetes Drugs

A large VA study found that staying on GLP-1 medications (such as semaglutide) for at least two years lowers major cardiovascular events by about 18% versus controls, but stopping the therapy leads to a rapid rebound in risk within six months—worsened by cost, side effects, and access barriers—highlighting the need for long-term maintenance and affordable access to these drugs.

via Gizmodo|
#cardiovascular-disease#glp-1s#health
Real-World Data Show Minimal Weight Regain After Stopping GLP-1 Obesity Drugs
health23 days ago

Real-World Data Show Minimal Weight Regain After Stopping GLP-1 Obesity Drugs

A Cleveland Clinic study of nearly 8,000 adults who stopped GLP-1 medications (such as Ozempic or tirzepatide) found only modest weight regain after one year (average 0.5%), suggesting real-world outcomes may diverge from clinical trials. Many patients either stay on some form of obesity treatment or switch to alternatives, with weight loss largely maintained when ongoing care and lifestyle support are in place, though results vary across populations and settings.

via Fox News|
#glp-1#health#ozempic
GLP-1 Weight-Loss Drugs Reveal Hidden Costs Beyond the Scale
health26 days ago

GLP-1 Weight-Loss Drugs Reveal Hidden Costs Beyond the Scale

A BuzzFeed Health feature examines how GLP-1 weight-loss medications (like Ozempic, Wegovy and Mounjaro) marketed for medical use are being used cosmetically, triggering a viral Reddit thread about a partner whose two-year Ozempic journey left her with a gaunt appearance, muscle loss, debt, and relationship strain. The piece highlights easy access via telehealth, aggressive marketing, and the risk of body dysmorphia or eating disorders when medical safeguards are bypassed. It emphasizes that these drugs are not miracle cures and should be paired with resistance training and adequate protein, while urging professional support for underlying psychological issues and broader societal pressures around body image.

via BuzzFeed|
#body-dysmorphia#glp-1-drugs#health
Oprah clears up Paris Fashion Week gait: vision, not age
entertainment27 days ago

Oprah clears up Paris Fashion Week gait: vision, not age

Oprah Winfrey explained that her deliberate, “90-year-old” walk into the Chloe show at Paris Fashion Week was due to not being able to see clearly, noting the sunglasses she wore weren’t prescription. She joked with Gayle King about both of them hobbling and addressed online trolls who teased her gait. Social media had linked the moment to Ozempic-type weight‑loss chatter, but Oprah also reiterated that she has previously disclosed using an unspecified GLP-1 weight‑loss medication as part of her health journey and said she won’t be shamed for it.

via Page Six|
#celebrity-news#entertainment#gayle-king
HIMS-Novo Wegovy Deal Triggers Bullish Analyst Revisions
market-news1 month ago

HIMS-Novo Wegovy Deal Triggers Bullish Analyst Revisions

Hims & Hers jumped about 49% after announcing a deal to offer Novo Nordisk’s Wegovy and Ozempic on its telehealth platform, a move that reduces legal risk as Novo dropped its lawsuit. Analysts at Citi, Deutsche Bank, Bank of America, and Needham issued more favorable views and higher price targets (up to about $30), signaling optimism that the partnership could unlock significant new revenue from official doses. TipRanks shows a Moderate Buy consensus with upside to current levels.

via TipRanks|
#glp-1#hims#market-news
FDA Warns Novo Nordisk for Underreporting Ozempic and Wegovy Adverse Events
health1 month ago

FDA Warns Novo Nordisk for Underreporting Ozempic and Wegovy Adverse Events

The FDA issued a warning letter to Novo Nordisk for serious postmarketing adverse drug event reporting violations related to the GLP-1 drugs Ozempic and Wegovy, citing three deaths (including a suicide) and a stroke report; the agency said Novo Nordisk failed to report deaths within the 15-day window and did not adequately investigate or report the suicide, though authorities have recently found no proven link between GLP-1s and suicide. Novo Nordisk has 15 days to report adverse reactions and two weeks to describe corrective actions; the company says it is addressing the concerns.

via WPXI|
#adverse-drug-events#fda#health
FDA flags Novo Nordisk for unreported side effects tied to Ozempic and Wegovy
health1 month ago

FDA flags Novo Nordisk for unreported side effects tied to Ozempic and Wegovy

The FDA sent Novo Nordisk a warning for serious lapses in reporting potential adverse events linked to semaglutide (the active ingredient in Ozempic and Wegovy), citing three deaths including a suicide and saying the company failed to investigate or report them within required timelines after an inspection of a New Jersey facility. Novo Nordisk says it will address the concerns, and the agency gave two weeks to outline corrective actions.

via NBC News|
#adverse-events-reporting#fda#health
Less Frequent GLP-1 Shots May Sustain Weight Loss, Small Study Finds
weight-loss1 month ago

Less Frequent GLP-1 Shots May Sustain Weight Loss, Small Study Finds

A small study of 30 adults suggests that reducing GLP-1 injections (tirzepatide or semaglutide) to intervals of 2–6 weeks can help maintain weight loss and improve health markers. Participants averaged about 36 weeks on reduced dosing with most keeping BMI stable; four regained some weight (largest gain 8 lb). Experts say tapering isn’t right for everyone and larger trials are needed, but this approach could lower long-term costs and treatment burden when paired with lifestyle changes.

via Healthline|
#glp-1#obesity#ozempic